Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St inches up on megacap strength; Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil slides on clues about Fed policy, rumors of Hormuz deal
- Dollar rises to session high after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
- Ovintiv adds 41,000 acres in Permian and Montney deals
Pfizer (PFE) Tops Q4 EPS by 15c, Beats on Revenue; Offers FY25 Guidance
February 4, 2025 6:46 AM ESTPfizer (NYSE: PFE) reported Q4 EPS of $0.63, $0.15 better than the analyst estimate of $0.48. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $17.28 billion.
GUIDANCE:
Pfizer sees FY2025 EPS of $2.80-$3.00, versus the consensus of $2.93. Pfizer... More
